Regenerative medicine company Orthocell Limited announced it has entered into an exclusive patent and trademark license agreement (Licence Agreement) and an exclusive distribution and supply agreement (Distribution Agreement) with BioHorizons Implant Systems Inc., a Delaware corporation (BioHorizons), under which Orthocell will grant BioHorizons an exclusive licence of two patent families covering a collagen scaffold for cell growth and a method for producing a collagen membrane, associated patent applications, improvements and
know-how and the Striate+ trademark (together, the Agreements). The licence relates to the Striate+TM products for dental and oral-maxillofacial procedures (the Field). The term of the licence is linked to the term of the supply and distribution agreement (25 years) (Term). In consideration for the exclusive licence, BioHorizons will pay Orthocell AUD 23.1 million1 (USD 16 million) within two business days of the date of execution. Striate+TM is a market leading resorbable collagen membrane used in guided bone and tissue regeneration
procedures. Its uptake is expected to be driven by surgeons' preference for high quality, easy to use devices facilitating better patient outcomes. Clinical studies 2 have shown Striate+TM supported transition from two- stage to single-stage dental procedures, reducing the procedure time by several months. This is of significant interest to patients and clinicians due to potential improvements in efficiency and efficacy of dental procedures.